- Home
- ABBV vs MRK Comparison
ABBV vs MRK Comparison
Compare ABBV & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABBV
- MRK
- Stock Information
- Founded
- ABBV 2012
- MRK 2000
- Country
- ABBV United States
- MRK United States
- Employees
- ABBV N/A
- MRK N/A
- Industry
- ABBV Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- ABBV Health Care
- MRK Health Care
- Exchange
- ABBV Nasdaq
- MRK Nasdaq
- Market Cap
- ABBV 303.1B
- MRK 260.8B
- IPO Year
- ABBV N/A
- MRK N/A
- Fundamental
- Price
- ABBV $175.62
- MRK $98.13
- Analyst Decision
- ABBV Strong Buy
- MRK Buy
- Analyst Count
- ABBV 22
- MRK 15
- Target Price
- ABBV $207.45
- MRK $129.07
- AVG Volume (30 Days)
- ABBV 6.8M
- MRK 14.0M
- Earning Date
- ABBV 01-31-2025
- MRK 02-04-2025
- Dividend Yield
- ABBV 3.74%
- MRK 3.30%
- EPS Growth
- ABBV N/A
- MRK 165.47
- EPS
- ABBV 2.87
- MRK 4.78
- Revenue
- ABBV $55,533,000,000.00
- MRK $63,174,000,000.00
- Revenue This Year
- ABBV $5.28
- MRK $7.49
- Revenue Next Year
- ABBV $5.73
- MRK $4.97
- P/E Ratio
- ABBV $61.18
- MRK $20.51
- Revenue Growth
- ABBV 0.72
- MRK 6.51
- 52 Week Low
- ABBV $153.09
- MRK $94.48
- 52 Week High
- ABBV $207.32
- MRK $134.63
- Technical
- Relative Strength Index (RSI)
- ABBV 47.03
- MRK 40.69
- Support Level
- ABBV $170.34
- MRK $97.82
- Resistance Level
- ABBV $178.13
- MRK $101.50
- Average True Range (ATR)
- ABBV 3.59
- MRK 2.19
- MACD
- ABBV 0.26
- MRK -0.19
- Stochastic Oscillator
- ABBV 40.68
- MRK 4.28
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.